Comparative randomised clinical trial against glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and soft-tissue infections.
暂无分享，去创建一个
[1] Steven D. Brown,et al. Inhibitory and Bactericidal Activities of Daptomycin, Vancomycin, and Teicoplanin against Methicillin-Resistant Staphylococcus aureus Isolates Collected from 1985 to 2007 , 2009, Antimicrobial Agents and Chemotherapy.
[2] C. Liao,et al. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[3] G. Oster,et al. Clinical and Economic Consequences of Failure of Initial Antibiotic Therapy for Hospitalized Patients With Complicated Skin and Skin-Structure Infections , 2008, Infection Control & Hospital Epidemiology.
[4] Steven D. Brown,et al. In vitro bactericidal activity of daptomycin against staphylococci. , 2002, The Journal of antimicrobial chemotherapy.
[5] K. Itani,et al. Outcomes Associated with Initial versus Later Vancomycin Use in Patients with Complicated Skin and Skin-Structure Infections , 2012, PharmacoEconomics.